Stephan Hjorth

List of Publications by Year in Descending Order

144 papers	8,224 citations	47 h-index	88 g-index
147 ext. papers	8,592 ext. citations	5.2 avg, IF	5.49 L-index

#	Paper	IF	Citations
144	The More, the Merrier? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective.. *Frontiers in Psychiatry*, **2021**, 12, 760181	5	3
143	Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction. *Frontiers in Psychiatry*, **2021**, 12, 727666	5	4
142	Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease. *Journal of Pharmacology and Experimental Therapeutics*, **2020**,	4.7	6
141	(3)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 374, 404-419	4.7	2
140	Does In Vitro Potency Predict Clinically Efficacious Concentrations?. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 298-305	6.1	13
139	Long-term incidence of serious fall-related injuries after bariatric surgery in Swedish obese subjects. *International Journal of Obesity*, **2019**, 43, 933-937	5.5	14
138	Revisions of Gastric Bypass-A Moral Obligation-Reply. *JAMA Surgery*, **2019**, 154, 975-976	5.4	1
137	Dose-Response-Time Data Analysis: An Underexploited Trinity. *Pharmacological Reviews*, **2019**, 71, 89-122	22.5	5
136	Reoperations After Bariatric Surgery in 26 Years of Follow-up of the Swedish Obese Subjects Study. *JAMA Surgery*, **2019**, 154, 319-326	5.4	27
135	In vivo potency revisited - Keep the target in sight. *Pharmacology & Therapeutics*, **2018**, 184, 177-188	13.9	19
134	Integration of Pharmacokinetic and Pharmacodynamic Reasoning and Its Importance in Drug Discovery. *Methods and Principles in Medicinal Chemistry*, **2018**, 367-398	0.4	1
133	Lost in translation: What? in an EC? Innovative PK/PD reasoning in the drug development context. *European Journal of Pharmacology*, **2018**, 835, 154-161	5.3	6
132	Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 271-279	18.1	90
131	Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain. *PLoS ONE*, **2017**, 12, e0168226	3.7	3
130	Discovery of New Drugs for Weight Loss and Prevention of Weight Regain **2016**, 247-284		
129	A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. *Neuropharmacology*, **2016**, 101, 519-30	5.5	10
128	Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation. *PLoS ONE*, **2016**, 11, e0167965	3.7	24

127	Looking back (and in)to the future: A personal reflection on 5-Serotonin autoreceptor function and antidepressant drug action(Hjorth et al., 2000). *Journal of Psychopharmacology*, **2016**, 30, 1129-1136	4.6	3
126	Pattern Recognition in Pharmacodynamic Data Analysis. *AAPS Journal*, **2016**, 18, 64-91	3.7	8
125	Modeling energy intake by adding homeostatic feedback and drug intervention. *Journal of Pharmacokinetics and Pharmacodynamics*, **2015**, 42, 79-96	2.7	7
124	Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. *Endocrinology*, **2015**, 156, 1237-41	4.8	3
123	Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples. *European Journal of Pharmaceutical Sciences*, **2015**, 67, 144-159	5.1	7
122	PK/PD Modeling of CNS Drug Candidates **2015**, 324-350		
121	Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach. *Pharmacology Research and Perspectives*, **2015**, 3, e00143	3.1	16
120	Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese mice. *Obesity*, **2014**, 22, 1287-95	8	12
119	Binding properties of antagonists to cannabinoid receptors in intact cells. *Fundamental and Clinical Pharmacology*, **2011**, 25, 200-10	3.1	12
118	Novel thioamide derivatives as neutral CB1 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 479-82	2.9	22
117	The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats. *Journal of Pharmacology*	4.7	17
116	The orphan receptor GPR55 is a novel cannabinoid receptor. *British Journal of Pharmacology*, **2007**, 152, 1092-101	8.6	1053
115	Identification and characterisation of a novel splice variant of the human CB1 receptor. *FEBS Letters*, **2005**, 579, 259-64	3.8	99
114	Osteoporosis in MCHR1-deficient mice. *Biochemical and Biophysical Research Communications*, **2004**, 318, 964-9	3.4	30
113	Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2003**, 367, 297-305	3.4	51
112	Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy. *European Neuropsychopharmacology*, **2002**, 12, 327-36	1.2	10
111	Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy. *Clinical Neuropharmacology*, **2001**, 24, 324-33	1.4	3
110	Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy. *Clinical Neuropharmacology*, **2000**, 23, 304-17	1.4	6

109	Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2000** , 362, 406-12	3.4	34
108	Introduction Neuroregulation of serotoninergic systems: basic and clinical perspectives. *Journal of Psychopharmacology*, **2000**, 14, 99-99	4.6	
107	Serotonin autoreceptor function and antidepressant drug action. *Journal of Psychopharmacology*, **2000**, 14, 177-85	4.6	148
106	Autoreceptors remain functional after prolonged treatment with a serotonin reuptake inhibitor. *Brain Research*, **1999**, 835, 224-8	3.7	21
105	The role of 5-HT1A autoreceptors and alpha1-adrenoceptors in the modulation of 5-HT release--III. Clozapine and the novel putative antipsychotic S 16924. *Neuropharmacology*, **1998**, 37, 349-56	5.5	16
104	Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. *NeuroReport*, **1998**, 9, 2985-8	1.7	98
103	Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. *Clinical Neuropharmacology*, **1997**, 20, 511-22	1.4	11
102	WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. *Neuropharmacology*, **1997**, 36, 461-5	5.5	75
101	Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. *Neuropharmacology*, **1997**, 36, 475-82	5.5	56
100	Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. *Metabolic Brain Disease*, **1997**, 12, 193-202	3.9	11
99	p-chloroamphetamine- and d-fenfluramine-induced brain serotonin release in experimental portal-systemic encephalopathy. *Metabolic Brain Disease*, **1997**, 12, 229-236	3.9	3
98	Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy **1997**, 12, 193		1
97	Effects of Ammonia and L-Tryptophan Loading on Brain Extracellular 5-HT and 5-HIAA Levels in Chronic Experimental Hepatic Encephalopathy **1997**, 201-207		
96	10-substituted 11-oxygenated (R)-aporphines: synthesis, pharmacology, and modeling of 5-HT1A receptor interactions. *Journal of Medicinal Chemistry*, **1996**, 39, 3491-502	8.3	31
95	(-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. *European Journal of Pharmacology*, **1996**, 303, 183-6	5.3	60
94	trans-2-Aryl-N,N-dipropylcyclopropylamines: synthesis and interactions with 5-HT(1A) receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 1485-93	8.3	24
93	Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo. *European Neuropsychopharmacology*, **1996**, 6, 317-22	1.2	15
92	Raphe 5-HT1A autoreceptors, but not postsynaptic 5-HT1A receptors or beta-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. *European Journal of Pharmacology*, **1996**, 316, 43-7	5.3	47

91	11-substituted (R)-aporphines: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions. *Journal of Medicinal Chemistry*, **1996**, 39, 3503-13	8.3	33
90	Acute effects of L-tryptophan on brain extracellular 5-HT and 5-HIAA levels in chronic experimental portal-systemic encephalopathy. *Metabolic Brain Disease*, **1996**, 11, 269-78	3.9	13
89	Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. *Journal of Neurochemistry*, **1995**, 64, 1238-44	6	34
88	Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. *Naunyn-Schmiedebergts Archives of Pharmacology*, **1995**, 352, 597-606	3.4	45
87	Evidence for 5-HT autoreceptor-mediated, nerve impulse-independent, control of 5-HT synthesis in the rat brain. *Synapse*, **1995**, 19, 170-6	2.4	63
86	(R)-11-hydroxy- and (R)-11-hydroxy-10-methylaporphine: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions. *Journal of Medicinal Chemistry*, **1995**, 38, 647-58	8.3	45
85	Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. *Neuropharmacology*, **1995**, 34, 89-96	5.5	50
84	Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release--I. BMY7378 and prazosin. *Neuropharmacology*, **1995**, 34, 615-20	5.5	63
83	Changes in the acoustic startle response and prepulse inhibition of acoustic startle in rats after local injection of pertussis toxin into the ventral tegmental area. *Psychopharmacology*, **1995**, 119, 71-8	4.7	17
82	Catecholamine-Containing Biodegradable Microsphere Implants: An Overview of Experimental Studies in Dopamine-Lesioned Rats. *Advances in Behavioral Biology*, **1995**, 421-427		1
81	Catecholamine-containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats. *Molecular Neurobiology*, **1994**, 9, 191-205	6.2	16
80	Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors. *European Journal of Pharmacology*, **1994**, 260, 251-5	5.3	88
79	Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. *Neuropharmacology*, **1994**, 33, 331-4	5.5	72
78	Effects of long-lasting voluntary running on the cerebral levels of dopamine, serotonin and their metabolites in the spontaneously hypertensive rat. *Life Sciences*, **1994**, 54, 855-61	6.8	22
77	5-HT1A autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo. *European Journal of Pharmacology*, **1993**, 238, 357-67	5.3	4
76	Synthesis of (+)-(R)- and (-)-(S)-5-hydroxy-2-methyl-2-dipropylaminotetralin: effects on rat hippocampal output of 5-HT, 5-HIAA, and DOPAC as determined by in vivo microdialysis. *Chirality*, **1993**, 5, 112-9	2.1	3
75	Local infusion of the selective 5HT-1b agonist CP-93,129 facilitates striatal dopamine release in vivo. *Synapse*, **1993**, 15, 90-2	2.4	64
74	Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. *Journal of Neurochemistry*, **1993**, 60, 776-9	6	222

73	Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1993**, 348, 339-46	3.4	48
72	(-)-Penbutolol as a blocker of central 5-HT1A receptor-mediated responses. *European Journal of Pharmacology*, **1992**, 222, 121-7	5.3	17
71	Acute reserpine treatment increases rat brain serotonin synthesis via a nerve impulse-dependent mechanism. *Journal of Neurochemistry*, **1992**, 58, 772-5	6	11
70	Differences in the in vitro and in vivo 5-hydroxytryptamine extraction performance among three common microdialysis membranes. *Journal of Neurochemistry*, **1992**, 59, 1778-85	6	31
69	Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1992**, 345, 137-43	3.4	56
68	The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1992**, 346, 12-9	3.4	31
67	Dopamine fiber growth induction by implantation of synthetic dopamine-containing microspheres in rats with experimental hemi-parkinsonism. *Molecular and Chemical Neuropathology*, **1992**, 16, 123-41		11
66	Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. *Life Sciences*, **1991**, 48, 1779-86	6.8	169
65	The putative 5-HT1B receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo: comparison with RU 24969. *European Journal of Pharmacology*, **1991**, 209, 249-52	5.3	84
64	Single-dose 8-OH-DPAT pretreatment does not induce tachyphylaxis to the 5-HT release-reducing effect of 5-HT1A autoreceptor agonists. *European Journal of Pharmacology*, **1991**, 199, 237-42	5.3	9
63	Effects of sexual interactions on the in vivo rate of monoamine synthesis in forebrain regions of the male rat. *Behavioural Brain Research*, **1991**, 46, 117-22	3.4	19
62	Microencapsulated dopamine (DA)-induced restitution of function in 6-OHDA-denervated rat striatum in vivo: comparison between two microsphere excipients. *Journal of Neural Transplantation & Plasticity*, **1991**, 2, 165-73		12
61	cis-(+)-8-OH-1-CH3-DPAT, (+)ALK-3, a novel stereoselective pharmacological probe for characterizing 5-HT release-controlling 5-HT1A autoreceptors. An in vivo brain microdialysis study. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1990**, 341, 149-57	3.4	12
60	Application of brain microdialysis to study the pharmacology of the 5-HT1A autoreceptor. *Journal of Neuroscience Methods*, **1990**, 34, 83-90	3	97
59	Stereoselectivity of Drug Receptor Interactions. *Drug Information Journal*, **1990**, 24, 485-496		
58	Effects of MDL 73005EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo. *European Journal of Pharmacology*, **1990**, 191, 391-400	5.3	48
57	Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: behavioural and in vivo brain microdialysis studies. *Life Sciences*, **1990**, 46, 955-63	6.8	113
56	Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomeryß conflict test. *Pharmacology Biochemistry and Behavior*, **1989**, 32, 259-65	3.9	94

55	Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum. *Journal of Neurochemistry*, **1989**, 52, 1170-82	6	75
54	Median raphe, but not dorsal raphe, application of the 5-HT1A agonist 8-OH-DPAT stimulates rat motor activity. *European Journal of Pharmacology*, **1989**, 160, 303-7	5.3	58
53	Partial postsynaptic 5-HT1A agonist properties of the novel stereoselective 8-OH-DPAT analogue (+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin, (+)ALK-3. *European Journal of Pharmacology*, **1989**, 170, 269-74	5.3	8
52	Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. *British Journal of Pharmacology*, **1989**, 98, 989-97	8.6	115
51	In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH23390. *Journal of Neural Transmission*, **1988**, 72, 83-97	4.3	32
50	Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?. *Pharmacology Biochemistry and Behavior*, **1988**, 30, 189-93	3.9	160
49	The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1988**, 338, 463-71	3.4	245
48	Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. *European Journal of Pharmacology*, **1988**, 152, 207-15	5.3	16
47	N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists. *Journal of Medicinal Chemistry*, **1988**, 31, 92-9	8.3	31
46	Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. *Neuroscience Letters*, **1988**, 92, 303-9	3.3	43
45	Injection of capsaicin into the nucleus raphe dorsalis elicits heat loss in the rat. *Neuroscience Letters*, **1987**, 75, 199-204	3.3	11
44	Region-selective activation of brain monoamine synthesis by sexual activity in the male rat. *European Journal of Pharmacology*, **1987**, 144, 77-82	5.3	35
43	C1- and C3-methyl-substituted derivatives of 7-hydroxy-2-(di-n-propylamino)tetralin: activities at central dopamine receptors. *Journal of Medicinal Chemistry*, **1987**, 30, 1827-37	8.3	14
42	(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist. *Journal of Medicinal Chemistry*, **1987**, 30, 2105-9	8.3	33
41	Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK&F 38393. *Psychopharmacology*, **1987**, 93, 534-7	4.7	40
40	Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm. *Psychopharmacology* , **1987**, 92, 371-5	4.7	21
39	Biphasic effect of L-5-HTP in the Vogel conflict model. *Psychopharmacology*, **1987**, 92, 96-9	4.7	25
38	Separation of dopaminergic and serotonergic inhibitory mechanisms in the mediation of estrogen-induced lordosis behaviour in the rat. *Pharmacology Biochemistry and Behavior*, **1987**, 27, 93-8	3.9	36

37	Anticonflict effects of low doses of the dopamine agonist apomorphine in the rat. *Pharmacology Biochemistry and Behavior*, **1986**, 24, 237-40	3.9	31
36	Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1986**, 333, 205-18	3.4	17
35	(+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors. *Journal of Neural Transmission*, **1986**, 65, 1-27	4.3	44
34	Suppression of lordosis behavior by the putative 5-HT receptor agonist 8-OH-DPAT in the rat. *European Journal of Pharmacology*, **1986**, 124, 361-3	5.3	55
33	The putatively selective dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 stimulate prolactin release in rats. *European Journal of Pharmacology*, **1986**, 130, 237-42	5.3	6
32	Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors?. *European Journal of Pharmacology*, **1986**, 129, 131-8	5.3	105
31	Stereoselective inhibition of prolactin secretion by (-)-HW-165, a novel 3-PPP congener; further support for similarities between central DA autoreceptors and pituitary lactotroph DA receptors. *European Journal of Pharmacology*, **1986**, 125, 421-8	5.3	7
30	Cardiovascular effects in the Sprague-Dawley rat of 8-hydroxy-2(di-N-propylamino) tetralin, a selective 5-hydroxytryptamine receptor agonist. *Journal of Pharmacy and Pharmacology*, **1985**, 37, 263-5	4.8	11
29	Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. *Journal of Neural Transmission*, **1985**, 62, 171-207	4.3	128
28	Hypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT. *Journal of Neural Transmission*, **1985**, 61, 131-5	4.3	218
27	Sub-chronic administration of (-)-3-PPP and central dopamine receptor sensitivity changes. *Journal of Neural Transmission*, **1985**, 64, 187-98	4.3	10
26	Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. *Journal of Neural Transmission*, **1985**, 62, 1-52	4.3	180
25	Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: discrepancies between in vitro and in vivo observations. *Life Sciences*, **1985**, 37, 673-84	6.8	36
24	(-)-Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis. *Neuropharmacology*, **1985**, 24, 1143-6	5.5	40
23	Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. *Journal of Medicinal Chemistry*, **1985**, 28, 215-25	8.3	66
22	Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. *Journal of Medicinal Chemistry*, **1985**, 28, 1049-53	8.3	36
21	Dopamine receptor-mediated hypothermia induced in rats by (+)-, but not by (-)-3-PPP. *European Journal of Pharmacology*, **1985**, 107, 299-304	5.3	18
20	Differential effects of the enantiomers of 3-PPP on dopamine D1-receptors of isolated rabbit retina. *Journal of Neural Transmission*, **1984**, 59, 1-7	4.3	8

19	8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists. *Journal of Medicinal Chemistry*, **1984**, 27, 45-51	8.3	63
18	C1-Methylated 5-hydroxy-2-(dipropylamino)tetralins: central dopamine-receptor stimulating activity. *Journal of Medicinal Chemistry*, **1984**, 27, 1003-7	8.3	10
17	Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). *European Journal of Pharmacology*, **1984**, 105, 365-8	5.3	194
16	Central monoaminergic effects of two aporphine analogues to the putative serotonin-receptor agonist, 8-hydroxy-2-di-n-propylaminotetralin. *Neuropharmacology*, **1984**, 23, 1187-90	5.5	4
15	Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity. *Journal of Medicinal Chemistry*, **1984**, 27, 1030-6	8.3	72
14	Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. *Psychopharmacology*, **1983**, 81, 89-99	4.7	184
13	The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat. *Psychopharmacology*, **1983**, 81, 14-7	4.7	17
12	Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity. *Journal of Medicinal Chemistry*, **1982**, 25, 925-31	8.3	30
11	Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings. *European Journal of Pharmacology*, **1982**, 83, 299-303	5.3	125
10	Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies. *European Journal of Pharmacology*, **1982**, 83, 131-4	5.3	21
9	A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]-N-n-propylpiperidine). *Journal of Neural Transmission*, **1982**, 53, 233-45	4.3	10
8	8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. *Journal of Neural Transmission*, **1982**, 55, 169-188	4.3	480
7	3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity. *Journal of Medicinal Chemistry*, **1981**, 24, 1475-82	8.3	91
6	3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. *Life Sciences*, **1981**, 28, 1225-38	6.8	202
5	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. *Journal of Medicinal Chemistry*, **1981**, 24, 429-34	8.3	30
4	8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. *Journal of Medicinal Chemistry*, **1981**, 24, 921-3	8.3	349
3	Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. *Pharmacology Biochemistry and Behavior*, **1981**, 15, 785-92	3.9	283
2	N-Alkylated 2-aminotetralins: central dopamine-receptor stimulating activity. *Journal of Medicinal Chemistry*, **1979**, 22, 1469-75	8.3	76

1 Pivaloyl esters of N,N-dialkylated dopamine congeners. Central dopamine-receptor stimulating activity. *Journal of Medicinal Chemistry*, **1978**, 21, 864-7 8.3 14